Most sickle cell disease patients who received the gene-editing therapy Casgevy have been free from vaso-occlusive crises for ...

Investing in biotech stocks isn't for everyone because the very nature of their business is fraught with risk. As a result, ...

Researchers at the meeting reported on long-term activity of commercialized gene therapies and preliminary data on ...

Vertex Pharmaceuticals Incorporated looks set for two new drug approvals in early 2025. Click here to read an analysis of ...

Cathie Wood of ARK Investment is one of Wall Street’s most well-known hedge fund bosses. In a hedge fund industry dominated ...

Two Saudi Arabian agencies signed on with Vertex Pharmaceuticals to help boost the countr | The Vertex agreement is part of ...

GSK, Gilead and Arcellx, Vertex and more present new data at the American Society of Hematology annual meeting just as sickle cell therapies Casgevy and Lyfgenia have a new outcomes-based payment ...

In 2024, startups saw a notable resurgence in large-scale funding rounds. By May, over 100 startups had secured funding ...

BMS isn’t the only firm trying to use degraders to tackle sickle cell disease. Novartis has a Wiz-targeting glue degrader, ...

-Company announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to CTX112 for the treatment of certain relapsed or refractory (R/R ...

Vertex Pharmaceuticals (VRTX) presented positive long-term data for its gene therapy Casgevy and issued a business update on ...

In particular, patients who had fewer than 10 annual vaso-occlusive events before the gene therapy were more likely to have ...